SCHEMBL5153434

SCHEMBL5153434

COC(=O)c1ccc(OC(Cl)N2CCCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
SLC6A3 Q01959 1/20 0.52
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
KDM4E B2RXH2 2/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
GLA P06280 1/20 0.47
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
MAPT P10636 4/20 0.46
NPC1 O15118 3/20 0.46
ALDH1A1 P00352 4/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5155659 0.85 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3CA1CA2
SCHEMBL2433437 0.84 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3CA1CA2
SCHEMBL2429238 0.82 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3CA1CA2
Hydrochloric Acid SCHEMBL2435965 0.82 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3CA1CA2
SCHEMBL2431062 0.82 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3CA1CA2
SCHEMBL2433276 0.80 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3CA1CA2
SCHEMBL2435527 0.80 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3CA1CA2
SCHEMBL5152638 0.79 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3CA1CA2
SCHEMBL2436081 0.79 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3CA1CA2
SCHEMBL6838647 0.74 L3MBTL1 (0.63) KDM4EGLARAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 SLC6A2 3889/4885SLC6A4 2377/4885SLC6A3 3977/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 SLC6A2 3775/4885SLC6A4 2165/4885SLC6A3 3920/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 SLC6A2 3650/4885SLC6A4 2159/4885SLC6A3 3798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.